A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given monthly for 4
doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical
treatments.